Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01885702 | Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI | unknown | Phase 1 / Phase 2 | 25 | Radboud University Medical CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05504265 | Perioperative Analgesia Modes in Minimally Invasive Esophagectomy | unknown | Phase 2 / Phase 3 | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 20, 2025 |
| NCT05042128 | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma(ASCEND) | unknown | Phase 2 | 158 | Australasian Gastro-Intestinal Trials GroupNETWORK | 2 | Oct 22, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06403709 | Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients | unknown | Phase 2 | 35 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT05830097 | A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 260 | Coherent Biopharma (Hefei) Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT06569459 | Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer | unknown | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT02949219 | Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | unknown | Phase 2 | 41 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05833815 | Addition of Everolimus to Standard of Care in Carcinoma Gallbladder | unknown | Phase 2 / Phase 3 | 56 | Banaras Hindu UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06463522 | Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 20 | Beijing 302 HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06341309 | Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 20 | West China HospitalOTHER | 0 | Aug 9, 2024 | clinicaltrials |
| NCT06475326 | Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer | unknown | Phase 2 | 87 | Fudan UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06543836 | ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer | unknown | Phase 2 | 68 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06546280 | A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation | unknown | Phase 2 | 38 | Zhujiang HospitalOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04636008 | Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer | unknown | Phase 1 / Phase 2 | 20 | West China HospitalOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06498752 | MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer | unknown | Phase 2 | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04483284 | Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients | unknown | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT05412589 | mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC | unknown | Phase 2 | 35 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06530784 | Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma | unknown | Phase 2 | 36 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06527495 | Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 150 | Assiut UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06516445 | SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC | unknown | Phase 2 | 33 | Huazhong University of Science and TechnologyOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06512428 | A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 138 | Shanghai Runshi Pharmaceutical Technology Co., LtdINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT05389527 | Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma(NeoLeap-HCC) | unknown | Phase 2 | 43 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06495853 | Prospective Phase II Study on Continuous Circumferential Reinforcement of Laparoscopic Rectal Anastomosis to Prevent Complications | unknown | Phase 2 | 208 | ZHI-ZHONG PANOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06496789 | Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer | unknown | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT04278222 | Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC) | unknown | Phase 2 | 24 | Shanghai Changzheng HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06387810 | Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer(undetermined) | unknown | Phase 2 | 45 | Peking Union Medical College HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT04715633 | PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer | unknown | Phase 2 | 53 | Sun Yat-sen UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05739045 | Nivolumab Combined With SOX Used in the Perioperative Treatment | unknown | Phase 2 | 46 | Xiangdong ChengOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03760822 | Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients(SOCRATE) | unknown | Phase 2 | 112 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT03959293 | Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | unknown | Phase 2 | 107 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT05229003 | Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC | unknown | Phase 2 | 44 | Fudan UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06090656 | Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)(BEST) | unknown | Phase 2 | 88 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06485713 | Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC | unknown | Phase 2 | 200 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06482008 | HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 0 | Jul 1, 2024 | clinicaltrials |
| NCT06475287 | HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 42 | Fudan UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06475417 | Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer | unknown | Phase 2 | 42 | Tang-Du HospitalOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT05444088 | Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 129 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06467565 | NALIRIFOX as Induction Therapy in LAPC | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06464614 | Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC. | unknown | Phase 2 | 54 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT03867799 | iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer | unknown | Phase 2 | 25 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05766748 | Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 30 | Cantex PharmaceuticalsINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06018896 | Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer(PTCA199-4) | unknown | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT05304234 | Liver Cancer Disparities in American Indian and Alaska Native Persons | unknown | Phase 2 | 200 | University of WashingtonOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06436976 | The Effect of Probiotics ATG-F4 in Cancer Patients | unknown | Phase 2 | 30 | Chungnam National University HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06437678 | Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer | unknown | Phase 2 | 50 | Zhejiang Cancer HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06434090 | Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 74 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Apr 4, 2025source: clinicaltrials